Want to see HK:2171 full AI Analyst Report?
2171 Stock Chart & Stats
HK$14.89
HK$0.27(2.96%)
At close: 4:00 PM EST
HK$14.89
HK$0.27(2.96%)
Day’s Range― - ―
52-Week RangeHK$10.87 - HK$28.60
Previous CloseN/A
Volume4.65M
Average Volume (3M)1.98M
Market Cap
HK$9.07B
Enterprise ValueHK$7.40K
Total Cash (Recent Filing)HK$1.12B
Total Debt (Recent Filing)HK$61.20M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Aug 25, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding601,457,000
10 Day Avg. Volume1,760,508
30 Day Avg. Volume1,977,652
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)9.40
Price to Sales (P/S)58.60
P/FCF Ratio-30.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.70Price Target Upside72.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)HK$433.36M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Profit ImprovementSubstantial 2025 revenue growth (~64%) with gross profit turning positive indicates the business is starting to scale core offerings. Durable revenue expansion and positive gross margin create a clearer path to operating leverage as R&D and fixed costs are spread over higher sales.
Improved Leverage And Sizeable Asset BaseMarked reduction in debt materially lowers near-term financing strain and interest obligations. Coupled with substantial assets and a remaining equity cushion, this improves solvency and provides a durable buffer to support continued clinical development and capital-intensive manufacturing.
Focused CAR‑T Platform And Manufacturing CapabilitiesA clear strategic focus on CAR‑T and end‑to‑end capabilities (discovery through manufacturing) is a durable competitive asset in cell therapy. Owning process and manufacturing know‑how supports faster trials, potential cost control, and differentiation in a capital‑intensive specialty area.
Bears Say
Negative Operating Cash FlowSustained negative operating cash flow (~-230.8M) requires recurring external financing to fund R&D and operations. Over months this persistent cash burn raises dilution and refinancing risk, and can constrain program execution if capital access tightens or terms deteriorate.
Large Ongoing Operating LossesSignificant operating losses despite revenue gains show the company is not yet profitable at the operating level. This structural loss profile reflects high fixed R&D and clinical costs, prolonging reliance on funding and delaying sustainable margin improvement absent material revenue scale or cost reduction.
Erosion Of Shareholder EquityMaterial decline in equity over several years signals cumulative losses and reduces the capital buffer. This erosion constrains financial flexibility, increases risk of dilutive financing or tougher capital terms, and weakens the balance sheet's ability to absorb setbacks in clinical development.
CARsgen Therapeutics Holdings Ltd. News
2171 FAQ
What was CARsgen Therapeutics Holdings Ltd.’s price range in the past 12 months?
CARsgen Therapeutics Holdings Ltd. lowest stock price was HK$10.87 and its highest was HK$28.60 in the past 12 months.
What is CARsgen Therapeutics Holdings Ltd.’s market cap?
CARsgen Therapeutics Holdings Ltd.’s market cap is HK$9.07B.
When is CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date?
CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 32 days.
How were CARsgen Therapeutics Holdings Ltd.’s earnings last quarter?
CARsgen Therapeutics Holdings Ltd. released its earnings results on Mar 06, 2026. The company reported -HK$0.046 earnings per share for the quarter, beating the consensus estimate of -HK$0.162 by HK$0.116.
Is CARsgen Therapeutics Holdings Ltd. overvalued?
According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Undervalued.
Does CARsgen Therapeutics Holdings Ltd. pay dividends?
CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.
What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?
CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.22.
How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?
CARsgen Therapeutics Holdings Ltd. has 601,457,000 shares outstanding.
What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?
CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.046 in its last earnings report, beating expectations of -HK$0.162. Following the earnings report the stock price went down -9.114%.
Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2171
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CARsgen Therapeutics Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
330.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.17%
Trailing 12-Months
Company Description
CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
2171 Stock 12 Month Forecast
Average Price Target
HK$25.70
▲(72.60% Upside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
JW (Cayman) Therapeutics Co. Ltd.
―
CStone Pharmaceuticals
―